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and Karin Jirström1Abstract
Aims: Previous studies have shown that membranous expression of podocalyxin-like protein (PODXL) is associated
with poor prognosis in colorectal cancer (CRC). In this study, we compared PODXL expression in primary CRC and
synchronous lymph node metastases. We further analyzed whether its expression changed in rectal tumours after
neoadjuvant radiation therapy.
Methods and results: The studied cohort consists of 73 consecutive patients from the South-Swedish Colorectal
Cancer Biobank. Immunohistochemical PODXL expression was examined on full-face sections from all primary
tumours and all 140 available lymph node metastases from 31 cases. Membranous PODXL expression was denoted
in 18/73 (24,7%) primary tumours, with a high concordance between primary and metastatic lesions. While all
negative primary tumours had negative metastases, some PODXL positive primaries had a varying proportion of
positive and negative metastatic lymph nodes. PODXL expression was also found to be mainly unaltered in pre-
and post-irradiation surgically resected tumour specimens in rectal cancer patients (n=16).
Conclusions: The findings in this study suggest that analysis of PODXL expression in the primary tumour is
sufficient for its use as a prognostic and treatment predictive biomarker in CRC, also in patients with metastatic
disease.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/9014177329634352Introduction
Every year more than 1,2 million people worldwide are
diagnosed with CRC and although CRC mortality is pro-
gressively declining, it still remains the second most
common cause of cancer death in the Western world.
Prognosis is mostly dependent on disease stage at diagno-
sis, however, outcome may vary considerably even within
the same tumour stage. Thus, there is a great need for
additional prognostic biomarkers to better identify pa-
tients with a high risk of developing metastases.* Correspondence: anna_h.larsson@med.lu.se
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reproduction in any medium, provided the orPodocalyxin-like protein (PODXL) is a transmembrane
glycoprotein with anti-adhesive properties, first identified
in the kidney where it plays a vital role in maintaining fil-
tration pathways [1]. PODXL is also expressed by vascular
endothelial cells [1], platelets [2], and hematopoietic stem
cells [3]. The role of PODXL in cancer was first described
in testicular cancer [4]. Since then, PODXL has been
found to be overexpressed in numerous cancer types and
associated with a more aggressive tumour phenotype and
poor outcome in breast [5], prostate [6], colorectal [7,8]
ovarian [9] and bladder cancer [10]. The poor prognosis
seems to be conferred by PODXL expression on the mem-
brane of tumour cells, and predominantly at the invasive
tumour front [7,11], further indicating an integral role for
this protein in the progression of some tumours.
Our previous studies have shown that PODXL is an
independent predictor of poor prognosis in CRC and aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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adjuvant treatment [7]. Given the potential clinical utility
of PODXL, we conducted the present study to investigate
the grade of concordance in terms of PODXL expression
between primary colorectal tumours and corresponding
lymph node metastases, and also the effect of neoadjuvant
radiation therapy on PODXL expression in rectal cancer.
Moreover, since previous studies were retrospective and
based on analysis of tissue-microarrays (TMAs), a second-
ary objective was to examine whether analysis of full-face




The study cohort included all patients in the prospective
South-Swedish Colorectal Cancer Biobank (STABB)
who were surgically treated for primary CRC at Skåne
University Hospital in Malmö, Sweden between January 1st
and September 30th 2012 (n=74). One patient with
complete histopathological response, i.e. abscence of
tumour cells in the surgical specimen post-irradiation,
was excluded from the study. Thirty-two (43,8%) of the
remaining 73 patients had lymph node metastases and
four (5,5%) had stage IV disease with liver metastases.
Median age at diagnosis was 72 years (range 44–92 years).
Twenty-one patients with rectal cancer received neo-
adjuvant radiation treatment. Eighteen of these patients
were given 25 Gy and three patients received a long
radiation therapy of 50,4 Gy combined with per oral
capecitabine prior to surgery.
Histopathological, clinical and treatment data were
obtained from pathology and hospital records. Patient
and tumour characteristics are summarized in Table 1.
The present study was approved by the Ethics Com-
mittee at Lund University (ref. 210/473 and 2012/307).
Written informed consent was obtained from each
patient.
Immunohistochemistry
All tumours were histopathologically re-evaluated by a
board certified pathologist (KJ). For each patient, one
representative paraffin block was selected from the pri-
mary tumour, and when applicable, all corresponding
metastases to lymph nodes (n=32). For rectal cancer pa-
tients who underwent neoadjuvant radiation therapy,
diagnostic pre-irradiation biopsies were also analyzed for
PODXL expression (n=16).
For immunohistochemical analysis, full-face sections
were automatically pre-treated using the PT-link system
(DAKO, Glostrup, Denmark) and then stained in an
Autostainer Plus (DAKO, Glostrup, Denmark) with the
affinity-purified polyclonal anti-PODXL antibody HPA
2110 (Atlas Antibodies, Stockholm, Sweden, diluted1:250). The specificity of this antibody, originally gener-
ated within the Human Protein Atlas (HPA) project, has
been validated using Western blotting and protein ar-
rays, and PODXL protein expression has been mapped
by immunohistochemistry in 48 types of normal tissues
and 20 common cancers (www.proteinatlas.org). The same
antibody was used to detect PODXL expression in CRC
in our previous studies [7,8] and in studies on bladder
[10], testicular [12] and pancreatic [11] cancer.Evaluation of PODXL staining
As in previous studies, PODXL staining was recorded as
negative (0), weak cytoplasmic positivity in any proportion
of cells (1), moderate cytoplasmic positivity in any propor-
tion (2), distinct membranous positivity in ≤ 50% of cells
(3) and distinct membranous positivity in > 50% of cells
(4) [7,8,10]. Overexpression of PODXL was considered if
the tumour cells exhibited a distinct membranous staining
in any proportion of the cells (3–4). Normal colorectal
mucosa adjacent to the cancers functioned as negative
control and tumour-associated vasculature as positive
control. The staining was evaluated by two independent
observers (AL and KJ) who were blinded to clinical and
outcome data. Scoring differences were discussed in order
to reach consensus.Statistics
Spearman’s Rho and Chi-square tests were used for
comparison of PODXL expression and relevant clinico-
pathological characteristics and to analyze the concor-
dance between PODXL expression in primary tumour
and metastases and between pre- and postirradiation
tumour samples. A p-value of 0.05 was considered statis-
tically significant. All statistical analyses were performed
using SPSS version 20 (SPSS Inc, Chicago, IL).Results
PODXL expression in primary tumours and its association
with clinicopathological parameters
Membranous PODXL expression was denoted in 18/73
(24,7%) primary tumours, Analysis of the relationship
between PODXL expression in primary tumours and
established clinicopathological parameters revealed a
strong correlation between PODXL overexpression and
low differentiation grade (p=0.020), presence of mucin-
ous histology (p=0.010) and female gender (p<0.010).
There were no statistically significant associations be-
tween PODXL expression and other clinicopathological
parameters including age at diagnosis, tumour location,
T-stage, N-stage and presence of vascular and neural
invasion (Table 1).
Table 1 PODXL expression and clinicopathological
parameters of the cohort
PODXL neg PODXL pos
n (%) 73 (100) 55 (75,3) 18 (24,7) p-value
Age
≤75 49 (67,1) 36 (65,5) 13 (72,2) 0.77
>75 24 (32,9) 19 (34,5) 5 (27,8)
Gender
Female 36 (49,3) 20 (36,4) 16 (88,9) <0,001
Male 37 (50,7) 35 (63,6) 2 (11,1)
T
1 2 (2,7) 1 (1,8) 1 (5,6) 0.62
2 13 (17,8) 11 (20,0) 2 (11,1)
3 46 (63,0) 35 (63,6) 11 (61,1)
4 12 (16,4) 8 (14,5) 4 (22,2)
N
0 40 (54,8) 34 (61,8) 6 (33,3) 0.09
1 21 (28,8) 14 (25,5) 7 (38,9)
2 12 (16,4) 7 (12,7) 5 (27,8)
M
0 69 (94,5) 52 (94,5) 17 (94,4) 0.99
1 4 (5,5) 3 (5,5) 1 (5,6)
Stage
I 11 (15,1) 9 (16,4) 2 (11,1) 0.24
II 28 (38,4) 24 (43,6) 4 (22,2)
III 30 (41,1) 19 (34,5) 11 (61,1)
IV 4 (5,5) 3 (5,5) 1 (5,6)
Diff grade
Intermed-high 58 (79,4) 48 (87,3) 10 (55,6) 0.02
Low 14 (19,2) 7 (12,7) 7 (38,9)
Missing 1 (1,4) 1 (5,6)
Mucinous histology
Absent 63 (86,3) 51 (92,7) 12 (66,7) 0.01
Present 10 (13,7) 4 (7,3) 6 (33,3)
Vascular invasion
Absent 57 (78,1) 45 (81,8) 12 (66,7) 0.2
Present 16 (21,9) 10 (18,2) 6 (33,3)
Neural invasion
Absent 67 (91,8) 52 (94,5) 15 (83,3) 0.16
Present 6 (8,2) 3 (5,5) 3 (16,7)
Location
Colon 40 (54,8) 28 (50,9) 12 (66,7) 0.29
Rectum 33 (45,2) 27 (49,1) 6 (33,3)
Neoadj radiation
(n=33)1
25 Gy 18 (54,5) 14 (51,8) 4 (66,7) 0.91
Table 1 PODXL expression and clinicopathological
parameters of the cohort (Continued)
50,4 Gy + cap 3 (9,1) 2 (7,4) 1 (16,7)
No 12 (36,4) 11 (40,7) 1 (16,7)
Adj treatment
Yes 19 (26,0) 8 (14,5) 11 (61,1) <0,001
No 54 (74,0) 47 (85,5) 7 (38,9)
1Rectal cancer patients only.
Larsson et al. Diagnostic Pathology 2013, 8:109 Page 3 of 7
http://www.diagnosticpathology.org/content/8/1/109Concordance between PODXL expression in primary
colorectal tumours and corresponding lymph node
metastases
PODXL expression could be evaluated in 31/32 (96,9%)
patients with lymph node metastases. The level of con-
cordance between primary colorectal tumours and re-
lated lymph node metastases was high (Table 2). In all
cases with a negative primary tumour, the same status
was observed in the lymph nodes. A discrepancy be-
tween positive primaries and a fraction of their corre-
sponding lymph nodes was however noted in 7 (22,6%)
cases. Sample immunohistochemical images of one dis-
crepant case is shown in Figure 1. In one case, the pri-
mary tumour had very few positive cells and the same
was seen in one of the lymph nodes, while the other two
lymph nodes were negative. Considering the median
value of PODXL expression in the lymph nodes for each
patient, the concordance of PODXL expression between
primary CRCs and lymph node metastases was 93,5%
and the correlation was statistically significant (p<0.001).
PODXL expression in rectal tumours pre- and post-
irradiation
PODXL expression could be evaluated in 16/21 (76,2%)
rectal biopsies pre-irradiation. Two (12,5%) were
PODXL positive and 14 (87,5%) PODXL negative. A dis-
crepancy between PODXL expression in tumours before
and after radiation therapy was noted in two cases
(Table 3). In both discrepant cases, positive conversion
(negative in the pre-irradiation biopsy and positive in
the post-irradiation tumour) was observed. Notably, 5/6
(83,3%) of the patients with PODXL positive rectal tu-
mours in the cohort were considered high-risk patients
and therefore received neoadjuvant radiation therapy.
Sample immunohistochemical images are shown in
Figure 2.
Discussion
When identifying new prognostic biomarkers it is of
great importance to decide which tumour site to exa-
mine, as the expression might differ in primary tumour
and metastases. In this study we have analyzed PODXL ex-
pression in 31 primary tumours and a total number of 140
corresponding lymph node metastases, thus providing a
Table 2 Concordance between PODXL expression in primary colorectal tumours and corresponding lymph node
metastases
Tumour PODXL No of Evaluable PODXL pos PODXL neg Concordance
Patient location prim tumour ln met ln met ln met (%) ln met (%) (%)
1 Colon Pos 4 4 25 75 25
2 Colon Pos 3 3 33.3 66.7 33.3
3 Colon Pos 20 17 58.8 41.2 58.8
4 Colon Pos 3 3 66.7 33.3 66.7
5 Colon Pos 5 5 80 20 80
6 Colon Pos 6 5 80 20 80
7 Colon Pos 2 2 100 0 100
8 Colon Pos 2 2 100 0 100
9 Rectum Pos 10 10 80 20 80
10 Rectum Pos 2 2 100 0 100
11 Rectum Pos 3 3 100 0 100
12 Colon Neg 14 14 0 100 100
13 Colon Neg 2 2 0 100 100
14 Colon Neg 2 1 0 100 100
15 Colon Neg 3 3 0 100 100
16 Colon Neg 1 1 0 100 100
17 Colon Neg 5 5 0 100 100
18 Colon Neg 1 1 0 100 100
19 Colon Neg 14 14 0 100 100
20 Colon Neg 1 1 0 100 100
21 Rectum Neg 4 3 0 100 100
22 Rectum Neg 2 2 0 100 100
23 Rectum Neg 1 1 0 100 100
24 Rectum Neg 8 6 0 100 100
25 Rectum Neg 1 1 0 100 100
26 Rectum Neg 3 2 0 100 100
27 Rectum Neg 1 1 0 100 100
28 Rectum Neg 5 5 0 100 100
29 Rectum Neg 2 1 0 100 100
30 Rectum Neg 1 1 0 100 100
31 Rectum Neg 9 9 0 100 100
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settings. Moreover, we have examined the potential ef-
fect of radiation therapy on PODXL expression in rectal
cancer patients.
PODXL has previously been found to correlate with a
poor prognosis in CRC [7,8]. So far, all results are derived
from studies based on TMAs with retrospectively col-
lected tumour samples. In this study, we used full-face
sections, one from each case, to determine PODXL
expression in 73 CRC patients. Our results indicate that
by use of full-face section analysis, a larger proportion of
tumours are identified as being PODXL positive, i.e.having membranous expression, compared to TMA-based
analyses (24,7% vs 8-13%) [7,8]. These findings are not
unexpected, since PODXL is, in the vast majority of cases,
overexpressed in a heterogenous fashion, preferrably at
the invasive tumour front. Therefore, use of the TMA-
technique will most likely lead to an underestimation of
positive cases. Moreover, no tumour in this cohort had
membranous staining in more than 50% of the tumour
cells (i.e. category 4), which may be explained by the size
of the cohort, but could also be attributed to the tumour
area selected for sampling. The number of cases denoted
as having > 50% cells with membranous PODXL ex-
Figure 1 Immunohistochemical sample images from one case with positive membranous PODXL staining in the primary tumour (A),
and corresponding positive (B,C) and negative (D) lymph node metastases.
Larsson et al. Diagnostic Pathology 2013, 8:109 Page 5 of 7
http://www.diagnosticpathology.org/content/8/1/109pression in previous studies is however negligible, further
supporting that using a cutoff based on the presence or
absence of membranous staining should be sufficient for
prognostication purposes. Even if recognition of mem-
branous PODXL expression is fairly straightforward, and
the mere presence rather than the quantity seems to be of
prognostic importance, it would however be of interest to
compare visual scoring and automated analysis in future
studies [13,14].
For characterization of key molecular alterations and
expression of investigative biomarkers in tumours from
large patient cohorts, whether retrospectively or pro-
spectively defined, the TMA-technology is indispensable
[15]. For prospective biomarker studies and in clinical
use, however, analysis of full-face sections should be the
most convenient and applicable method.
Prognostic biomarkers in CRC are routinely analyzed in
the primary tumor, whereas tumor cells in lymph node
metastases are not characterized. Previous studies on
KRAS expression have shown a discrepancy between the
primary tumour and corresponding lymph node
metastases [16,17], whereas the expression of otherTable 3 Concordance between PODXL expression in
rectal tumour samples pre- and post-irradiation therapy
Post-irradiation
Pre-irradiation PODXL neg PODXL pos
(n=12) (n=4)
PODXL neg 12 2
PODXL pos 0 2
p=0,050biomarkers, e.g. ER and HER-2 in breast cancer have been
demonstrated to be highly concordant [18]. Of note, while
most studies related to the concordance between primary
and metastatic lesions have only examined a few lymph
nodes (typically two per patient), we have in this study
strived to examine all metastatic lymph nodes.
Although there was a discordance of PODXL expression
between primary tumours and lymph node metastases in
some cases, this was limited to a few cases with PODXL
positive primaries where a clonal distribution of PODXL
expression was observed in the metastatic lymph nodes.
These results reflect the fact that the small proportion of
cells in a positive primary tumour displaying membranous
PODXL expression are highly prone to metastasize. The
excellent concordance between primary tumour and
lymph node metastases demonstrate that assessment of
the primary tumour is sufficient to determine if a patient
has a PODXL positive tumour. The expression of PODXL
in lymph node metastases can however provide prognostic
information when no primary tumour is available for ana-
lysis. Moreover, in future studies, it would be of interest to
perform in-depth analyses of other molecular characteris-
tics, and drivers of the metastatic phenotype, that may
differ between PODXL negative and positive lymph node
metastases in individual cases.
The significant associations between PODXL expression
and several unfavourable clinicopathological characteristics
(e.g. TNM stage) that have been demonstrated in our previ-
ous studies [7,8], did not reach statistical significance in this
study, most likely due to the small sample size. Neverthe-
less, despite the small number of patients, a statistically sig-
nificant relationship between PODXL expression and
Figure 2 Immunohistochemical sample images from one rectal
cancer case with positive membranous PODXL staining in the
pre-irradiation biopsy (A), surgical resection specimen of
primary tumour post-irradiation (B) and lymph node
metastasis (C).
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Moreover, there was an overweight of PODXL positive tu-
mours among patients who received adjuvant treatment, an
indirect measurement of more aggressive tumours. The sig-
nificant association of PODXL expression with female ge-
nder has not been observed in previous studies and is likely
attributable to the small size of the cohort.It is well known that approximately half of the patients
with CRC stage III disease will relapse, and that adjuvant
chemotherapy reduces the risk of recurrence with 20-30%.
Our previous study has shown that patients with PODXL
positive tumours within this group benefit from adjuvant
chemotherapy irrespective of treatment regime [7]. While
the majority of patients with stage III disease in this study
received adjuvant treatment, a few patients were not con-
sidered candidates for chemotherapy due to old age or co-
morbidity. In cases of doubt whether adjuvant treatment
should be given, assessment of PODXL expression may be
a useful prognostic tool. Moreover, the finding of a higher
proportion of PODXL positive tumours in full-face sec-
tions is of particular clinical relevance in stage II disease,
where it is of uttermost importance to identify patients
with high-risk disease who would benefit from adjuvant
treatment. Previous studies have shown that adjuvant
chemotherapy could improve survival for this group of
patients, but that the incremental benefits are small [19].
Therefore, further prognostic tools are needed to better
guide treatment decisions in this patient category. As
PODXL expression has been demonstrated to have a
prognostic value in patients with stage II disease in retro-
spective analysis [7] this association warrants further study
in the prospective setting.
In biomarker studies it is important to consider the ef-
fect of neoadjuvant treatment on biomarker expression. In
this study we found an excellent concordance between
PODXL expression in rectal tumours before and after
neoadjuvant irradiation, suggesting that PODXL expres-
sion is not affected by radiation therapy.
In conclusion, the results from this study suggest that
PODXL expression in CRC is concordant in primary
tumours and corresponding lymph node metastases in
individual patients, and also remains unaffected by
neoadjuvant radiation therapy. The results further sup-
port the clinical utility of PODXL as a biomarker for risk
assessment in CRC, even in cases where no primary
tumour is available for analysis, and irrespective of histo-
pathological response to neoadjuvant treatment.
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